Ikena Oncology, Inc.
IKNA
$-0.06
Change (1 day)
$2.30
Year High
$1.22
Year Low
Categories
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Ikena Oncology, Inc. (IKNA) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | -109,156,000 | 22.34 M | 192.09 M | 178.66 M | |
| 2022 | -54,225,000 | 25.29 M | 172.26 M | 160.01 M | |
| 2021 | -225,231,000 | 40 M | 247.88 M | 236.52 M | |
| 2020 | -162,305,000 | 269.45 M | 168.4 M | 165.97 M | |
| 2019 | -3,216,000 | 147.44 M | 85.97 M | 85.21 M |